The Pamela Sklar Division of Psychiatric Genomics is a joint effort between the Department of Genetics and Genomic Sciences, the Department of Psychiatry and the Icahn Institute for Data Science and Genomic Technology. The division is dedicated to improving treatment options and care for the millions of patients affected by diseases such as schizophrenia, bipolar disorder, major depressive disorder, and obsessive-compulsive disorder.
Our approach pulls together all relevant data to build a comprehensive analysis of how these diseases function. We rely on the best and most innovative technologies, including DNA sequencing and advanced computational biology. We hope to shape future psychiatric treatments by using modern genomics to understand the biology and risk of developing psychiatric disease.
Current areas of research include large scale genome-wide association studies, rare variant identification through next-generation sequencing, biological follow-up of candidate genes, transcriptional analysis of RNA from postmortem human brain, and the generation and study of pathways and biology in induced pluripotent stem cells from patients.
Our molecular translational laboratories focus on understanding the pathobiology for each psychiatric disease, while our clinical trials conduct early-stage investigations for new treatments and tests for neuropsychiatric disorders.
Learn more about the mission of the Pamela Sklar Division of Psychiatric Genomics